Table 5

 Shoulder disorders in relation to lifetime upper arm elevation above 90°; total study population (n = 1886)

Lifetime exposure (mth)Dominant shoulderLifetime exposure (mth)Non-dominant shoulder
nc%ORcrudeORadj95% CInc%ORcrudeORadj95% CI
n, number of subjects; c, number of cases; %, prevalence, ORcrude, unadjusted odds ratio; ORadj, adjusted odds ratio (adjusted for 10 year age categories (30–40, 40–50, 50–60, 60–70) and categorised pack-years of smoking (0, 0–20, 20); age and smoking categories include the lower limit and exclude the upper limit).
Subjects were classified as right handed if they used both hands equally well.
In analyses for the non-dominant shoulder, 14 subjects with lifetime upper arm elevation ⩾24 months were included in the category ⩾12 months. Two of these subjects had shoulder pain with disability, none of them had shoulder tendinitis or shoulder pain without disability
Exposure categories include the lower limit and exclude the upper limit.
Supraspinatus tendinitis
0–6491102.01.001.000–642930.71.001.00
6–1242771.60.800.730.27 to 1.946–1268281.21.690.970.25 to 3.85
12–24519142.71.331.300.57 to 2.99⩾1268671.01.460.540.13 to 2.24
⩾24315175.42.741.870.79 to 4.44
Trend analysis (for an increment of 6 months):Trend analysis (for an increment of 6 months):
ORadj 1.14 (95% CI 0.97 to 1.35)ORadj 0.64 (95% CI 0.39 to 1.08)
Shoulder pain with disability
0–6486234.71.001.000–642871.61.001.00
6–12423215.01.051.040.56 to 1.936–12682233.42.101.430.59 to 3.43
12–24517458.71.921.751.03 to 2.97⩾12685446.44.131.930.81 to 4.57
⩾243134915.73.742.231.28 to 3.88
Trend analysis (for an increment of 6 months):Trend analysis (for an increment of 6 months):
ORadj 1.18 (95% CI 1.06 to 1.30)ORadj 1.26 (95% CI 0.97 to 1.64)
Shoulder pain without disability
0–64865411.11.001.000–6428348.01.001.00
6–124235011.81.071.110.74 to 1.706–12682598.31.101.100.71 to 1.71
12–245178817.01.641.681.16 to 2.44⩾12685679.81.261.390.82 to 1.93
⩾243134815.31.451.851.16 to 2.94
Trend analysis (for an increment of 6 months):Trend analysis (for an increment of 6 months):
ORadj 1.16 (95% CI 1.06 to 1.27)ORadj 1.19 (95% CI 0.97 to 1.46)